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Abstract: Gliomas frequently display constitutive activation of the transcription factor STAT3, a protein that is known to 
be able to mediate neoplastic transformation. STAT3 regulates genes that play a central role in cellular survival, prolifera-
tion, self-renewal, and invasion, and a cohort of STAT3 target genes have been found that are commonly coexpressed in 
human cancers. Thus, these genes likely subserve the transforming ability of constitutively activated STAT3. To determine 
whether the coordinated expression of STAT3 target genes is present in a subset of human gliomas, and whether this changes 
the biology of these tumors in patients, gene expression analysis was performed in four distinct human glioma data sets for 
which patient survival information was available. Coordinate expression of STAT3 targets was signiﬁ  cantly associated with 
poor patient outcome in each data set. Speciﬁ  cally, patients with tumors displaying high expression of STAT3 targets had 
a shorter median survival time compared to patients whose tumors had low expression of STAT3 targets. These data suggest 
that constitutively activated STAT3 in gliomas can alter the biology of these tumors, and that development of targeted STAT3 
inhibitors would likely be of particular beneﬁ  t in treatment of this disease.
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Introduction
Central nervous system malignancies remain among the most difﬁ  cult tumors to treat, owing to both 
anatomic and biologic features. The intimate association with critical structures and the highly vascular 
and inﬁ  ltrating nature of gliomas make complete surgical resection particularly difﬁ  cult. Furthermore, 
these tumors often manifest an intrinsic resistance to cell death triggered by cytotoxic agents or 
radiotherapy. To enhance our approach to the treatment of this disease it would be valuable to understand 
the molecular abnormalities that underlie these tumors.
A number of mutations have been found to occur commonly in human gliomas (Holland, 2001; 
Maher, 2001). One recurrent ﬁ  nding is the activation of tyrosine kinases, particularly the epidermal 
growth factor (EGF) receptor. The EGF receptor may be constitutively activated as a result of overex-
pression or from structural mutations that render the catalytic domain continually activated (Bigner, 
1990; Libermann, 1985). In addition, activation of the platelet-derived growth factor (PDGF) receptor 
can occur due to concomitant overexpression of both the receptor and the PDGF ligand (Guha, 1995). 
Another soluble factor that can promote mitogenesis of normal and malignant glial cells is interleukin 
(IL)-6 (Van Meir, 1990). IL-6 can display enhanced expression in human gliomas (Tchirkov, 2001) as 
well as murine models of glial tumors (Weissenberger, 2004). Although each of these soluble proteins 
can activate a number of signaling pathways, one transcription factor that plays a central role in trans-
ducing signals from EGF, PDGF, and IL-6 is STAT3 (Alvarez, 2006).
Under basal conditions, STAT3 is found in the cytoplasm. Once activated through phosphorylation 
of a unique carboxy-terminus tyrosine residue, STAT3 forms dimers, translocates to the nucleus, and 
binds to nine base pair sequences in the promoter regions of target genes thereby activating (or in some 
cases repressing) transcription (Darnell, 1997; Ihle, 1996). STAT3 targets include genes involved in 
cell cycle progression, survival, self-renewal, and invasion (Alvarez, 2005). Reﬂ  ecting these physio-
logical functions of STAT3 target genes, STAT3 has been found to be activated inappropriately in a 
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wide array of human tumors, including gliomas 
(Frank, 2003). In fact, in at least some systems, 
activation of STAT3 is sufﬁ  cient to lead to neo-
plastic transformation of cells (Bromberg, 1999). 
STAT3 activation is likely to be directly involved 
in the pathogenesis of CNS tumors as depleting 
STAT3 through RNA interference can lead to 
apoptosis in astrocytoma cell lines (Konnikova, 
2003). The activation of STAT3 in human gliomas 
may be of particular clinical importance in that, 
through activation of pro-survival genes, constitu-
tive STAT3 activation can confer resistance to 
ionizing radiation and cytotoxic chemotherapy in 
other tumor systems (Alas and Bonavida, 2003).
Although understanding speciﬁ  c target genes is 
an important approach for dissecting the mecha-
nism by which a transcription factor can contribute 
to oncogenesis, much information can also be 
gleaned from analyzing global patterns of target 
gene expression (Alvarez and Frank, 2004). In fact, 
analyzing the coordinate expression of STAT3 
target genes has proven to be a powerful approach 
to determine the presence of functionally active 
STAT3 in a cell (Alvarez, 2005). Given the central 
role that these genes play in the biology of a cell, 
identiﬁ  cation of a STAT3 gene expression signature 
in a tumor may connote speciﬁ  c prognostic infor-
mation. For example, it is known that STAT3 
activation is associated with a decreased survival 
in acute leukemia and other tumors (Benekli, 
2002). Furthermore, the presence of a STAT3 gene 
expression signature may identify tumors appropri-
ate for molecular therapy speciﬁ  cally targeting this 
transcription factor (Darnell, 2002; Frank, 2006). 
Finally, recent evidence has suggested that 
grouping gliomas based on gene expression might 
be a better predictor of survival than histologic 
classiﬁ  cation (Nutt, 2003).
To determine whether coordinate expression of 
STAT3 target genes carries prognostic information 
in human glial tumors, we analyzed expression 
of STAT3 target genes in primary gliomas, and 
examined the relationship of this pattern of gene 
expression to patient survival.
Materials and Methods
Datasets
To assess the relationship between expression of 
STAT3 target genes and survival in glioma, we 
analyzed four independent gene expression data 
sets for which information was available on both 
gene expression and patient survival. The use of 
these disparate data sources also allowed us to 
avoid artifacts arising from distinctions in institu-
tional clinical assessment or differences in gene 
expression methodology on primary tumor sam-
ples. Speciﬁ  cally, we analyzed a cohort of 29 high 
grade gliomas with non-classical histology from 
several hospitals in Europe and North America 
(Nutt, 2003); a cohort of 74 grade III and IV glio-
mas from the University of California, Los Ange-
les (Freije, 2004); the BWH Glioma GeneChip 
Dataset (Chakravarti et al. manuscript in prepara-
tion), encompassing 29 gliomas, three quarters of 
which were glioblastoma multiforme; and, a cohort 
of 21 classic gliomas (Nutt, 2003).
Gene set enrichment analysis (GSEA)
To determine if STAT3 target genes were enriched 
in poor-outcome tumors, we performed gene set 
enrichment analysis (GSEA; Subramanian, 2005). 
Brieﬂ  y, all genes for which expression data was 
available were ranked based upon differential 
expression between poor-outcome and good-
outcome classes using the signal-to-noise metric. 
The distribution of STAT3 targets on this ranked 
list was then assessed using a Kolmogorov-
Smirnov distribution test, which produces a 
normalized enrichment score (NES), a measure of 
the extent to which STAT3 targets are enriched in 
one class or the other. The normalized enrichment 
score for each analysis is shown in Figure 1. The 
statistical significance of this enrichment was 
evaluated by performing permutation testing using 
randomized class labels, thereby generating a 
nominal p value. To account for multiple hypoth-
esis testing, the enrichment score was normalized, 
and a q value of the false discovery rate (FDR) was 
calculated (Reiner, 2003). A q value  0.25 is con-
sidered signiﬁ  cant. Both the p value and the FDR q 
value are provided for each analysis.
STAT3 target genes were deﬁ  ned in three ways. 
First, analyzing genes directly responsive to 
activation of STAT3 in a cell culture system 
yielded approximately 100 STAT3 targets (Alvarez, 
2005). Recognizing that only a subset of these 
genes was likely to be coexpressed in human 
tumors, coordinate expression of these 100 genes 
was analyzed in a dataset of 190 human tumors. 
This analysis revealed a group of 12 genes, known 
as a STAT3 signature, that showed strong 
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co-association in these human tumors. The 12 
genes in this group are: vascular endothelial 
growth factor (VEGF), protein tyrosine phospha-
tase (PTP)-CAAX1, kruppel-like factor (KLF)-4, 
exostosin (Ext)-1, Neimann-Pick C1 (NPC1), 
p21-activated kinase (Pak)-2, Mcl-1, JunB, Bcl-6, 
NF-IL3, calpain-2, and early growth response 
(Egr)-1. Finally, examining expression of STAT3 
target genes in 96 primary human breast cancers 
displaying histological evidence of tyrosine phos-
phorylated STAT3, a subset of 300 STAT3 target 
genes was independently identiﬁ  ed.
Hierarchical clustering
Hierarchical clustering was performed to separate 
gliomas on the basis of STAT3 target gene expres-
sion using dChip software.
Results
Given that STAT3 activation is a common and 
biologically important ﬁ  nding in gliomas, and that 
clustering gliomas based on gene expression 
provides powerful prognostic information, we 
sought to determine whether a STAT3 gene 
expression signature was associated with a distinct 
clinical outcome in this disease. We ﬁ  rst investi-
gated a well characterized cohort of 29 high grade 
gliomas that displayed histologic features which 
could not be classiﬁ  ed deﬁ  nitively by experienced 
neuropathologists (Nutt, 2003). Patient survival 
data were available for each of these tumors allow-
ing us to directly address the question of whether 
tumors that showed enhanced expression of STAT3 
targets had a difference in clinical outcome inde-
pendent of pathologic classification. To avoid 
discrepancies arising from delays in diagnosis or 
clinical assessment, patient survival from the time 
of diagnosis was divided into thirds, and gene 
expression proﬁ  les were compared between tumors 
from the third of patients who experienced the 
longest survival and from the third with the short-
est survival. GSEA revealed prominent enrichment 
of STAT3 target genes in the poor prognosis group 
Figure 1. Glioma patients with a short survival have tumors with enhanced expression of STAT3 target genes. Gene set enrichment analysis 
was performed comparing the short survival and long survival cohorts of each of three independent data sets (Subramanian, 2005). Normalized 
enrichment scores were calculated, and statistical signiﬁ  cance was determined by calculating a nominal p value by permutation testing, and, 
to account for multiple hypothesis testing, an FDR q value was determined. *, FDR q value  0.25; #, FDR q value  0.25 and p value 
 0.05.
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of these gliomas, whether defined by the 
full complement of STAT3 targets (p   0.01; 
FDR q = 0.02), the 12 gene STAT3 signature 
(p   0.01; FDR q = 0.02), or the STAT3 target 
genes enriched in tumors with tumors with histo-
chemical evidence of STAT3 phosphorylation (p 
= 0.06; FDR q = 0.03) (Fig. 1).
We next evaluated a cohort of 74 grade III and 
grade IV gliomas from patients treated at the 
University of California, Los Angeles (Freije, 
2004). To allow clear assessment of outcome, 
patient survival was again divided into thirds, and 
gene expression proﬁ  les were compared between 
tumors from the third of patients who experienced 
the longest survival and from the third with the 
shortest survival. Once again, strong associations 
were seen for expression of the STAT3 target 
genes in the poor prognosis tumors using the gene 
sets defined by histologic evidence of STAT3 
activation (p = 0.02; FDR q = 0.19), the 12 gene 
STAT3 signature (p = 0.18; FDR q = 0.18), and the 
complete set of STAT3 target genes (p = 0.18; FDR 
q = 0.16) (Fig. 1).
To further validate that STAT3 target gene 
expression was associated with a poor prognosis 
in gliomas, we analyzed a distinct set of 29 tumors 
(greater than 75% of which were glioblastoma 
multiformes) for which survival was bifurcated 
into greater than or less than two years (BWH 
Glioma GeneChip Dataset; Chakravarti et al. 
manuscript in preparation). Once again, a signiﬁ  -
cant association was found with STAT3 target gene 
expression in the tumors of patients with short 
survival using the gene sets derived from the 
tumors with histochemical evidence of STAT3 
phosphorylation (p = 0.02; FDR q = 0.19), the 12 
gene STAT3 signature set (p = 0.12; FDR q = 0.09), 
and the full complement of STAT3 targets 
(p = 0.15; FDR q = 0.24) (Fig. 1).
We also evaluated an additional data set of 21 
classic gliomas, comprising 14 glioblastomas and 
7 oligodendrogliomas (Nutt, 2003). Although there 
was a notable enrichment of STAT3 signature 
genes in the tumors of patients with short survival, 
the small number of patients limited the statistical 
power. We thus took an alternative approach to 
address the correlation of STAT3 target genes with 
outcome in CNS tumors. Unsupervised hierarchi-
cal clustering of these gliomas was performed 
based upon the relative expression of STAT3 
targets (Fig. 2A). In this manner, tumors were 
separated into two well-deﬁ  ned groups. Eight of 
these tumors displayed high expression of STAT3 
targets (6 glioblastomas and 2 oligodendrogliomas) 
and 13 had relatively low expression (8 glioblas-
tomas and 5 oligodendrogliomas). We then evalu-
ated the survival of these two groups using 
Kaplan-Meier analysis. Patients whose tumors 
displayed high expression of STAT3 targets had a 
shorter median survival than the group without 
(Fig. 2B), indicating that enhanced expression of 
STAT3 targets correlates with poor outcome in 
these gliomas as well. When we performed 
hierarchical clustering using the STAT3 target 
genes enriched in tumors with histochemical 
evidence of STAT3 phosphorylation, the patients 
again segregated into two groups with signiﬁ  cantly 
different survival (data not shown). Taken together, 
these analyses on data sets from disparate institu-
tions and investigators indicate that a STAT3 gene 
expression signature is associated with a poor 
prognosis in malignant gliomas.
Discussion
The ﬁ  nding from these independent data sets that 
coordinate expression of well deﬁ  ned STAT3 target 
genes is associated with a worse prognosis likely 
reflects the physiologic function mediated by 
STAT3 and the genes it regulates. STAT3 target 
genes in general, and the 12 gene STAT3 gene 
expression signature in particular, include genes 
whose functions span the range of phenotypic 
abnormalities found in cancer (Hanahan and 
Weinberg, 2000). These include the promotion of 
cell cycle progression, (e.g. JunB and Egr-1) 
survival (e.g. Mcl-1), self-renewal, (e.g. Bcl-6 and 
Klf-4), and invasion and angiogenesis (e.g. vascu-
lar endothelial growth factor (VEGF)). Thus, it is 
not surprising that activation of STAT3, and ele-
vated expression of the genes controlled by this 
transcription factor, may confer a more aggressive 
phenotype on gliomas cells. For example, a 
pro-survival gene such as Mcl-1 may mediate 
resistance to apoptosis, thereby rendering therapies 
such as radiation and chemotherapy less effective. 
It is also possible that other biological features of 
malignant glial cells are altered in such a way as 
to render these tumors more difﬁ  cult to eradicate. 
For example, heightened expression of c-met may 
increase the mobility and invasiveness of gliomas, 
thereby making them more difﬁ  cult to surgically 
extirpate (Abounader, 2001). Similarly, another 
STAT3 target gene, VEGF, may be of particular 
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Figure 2. STAT3 target gene expression is associated with a shorter survival in gliomas. (A) Segregation of gliomas based on STAT3 target 
gene expression. Unsupervised hierarchical clustering was performed on a data set of 21 gliomas (Nutt, 2003) (http://www.broad.mit.edu/cgi-
bin/cancer/datasets.cgi) based on expression of STAT3 targets using dChip software. Eight tumors displayed high STAT3 target gene 
expression and 13 displayed low expression. (B) Kaplan-Meier analysis of survival of gliomas based on expression of STAT3 target 
genes.
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importance in enhancing the angiogenesis of 
gliomas, which are often highly vascular (Plate, 
1992). It is also notable that while these STAT3 
signature genes were initially deﬁ  ned in murine 
ﬁ  broblasts, they have been validated in human 
tumors of lineages as divergent as hematologic 
cells and glia (Alvarez, 2005). This suggests that 
fundamental aspects of STAT3 signaling are likely 
maintained across tissue types.
A recent study has suggested that STAT3 
phosphorylation in glioblastomas and anaplastic 
astrocyotmas, as assessed by immunohistochem-
istry, correlates with expression of mutant EGF 
receptors (EGFRvIII), and was not a strong 
prognostic marker (Mizoguchi, 2006). However, 
the difference in ﬁ  ndings between that study and 
the current one may reﬂ  ect fundamental differences 
arising from the methodology used. In determining 
the activation state of a transcription factor such 
as STAT3, several methods can be utilized. STAT3 
activation has been assessed in tumors most 
commonly by assessing the phosphorylation state 
of the protein (using immunohistochemistry or 
immunoblotting) or determining the presence of 
nuclear STAT3 dimers competent to bind to DNA 
(using electrophoretic mobility shift analysis). 
Identiﬁ  cation of expression of STAT3 target genes 
complements these techniques, and provides a 
number of additional advantages. Since the effects 
of STAT3 in promoting malignant transformation 
in general, or the more malignant phenotype of 
gliomas as reported here, are mediated through its 
target genes, identiﬁ  cation of a STAT3 gene expres-
sion signature is perhaps the most direct way to 
assess the functional activation of this protein. In 
addition, it is certainly possible that transient or 
intermittent STAT3 activation may occur which 
may limit the ability to detect activated STAT3 by 
biochemical means, whereas the more prolonged 
activation of expression of target genes may be 
more likely to be detected over a larger temporal 
window. Conversely, it is conceivable that STAT3 
activation can occur in the setting of chromatin 
modiﬁ  cations or the presence of transcriptional 
repressors that will attenuate the expression of 
STAT3 target genes. The absence of expression of 
STAT3 target genes in this situation would appro-
priately exclude these tumors from therapeutic 
considerations that might otherwise apply to 
tumors displaying functionally activated STAT3.
We chose instead to use the presence of a STAT3 
gene expression signature as a surrogate for STAT3 
activation. This signature was identiﬁ  ed in vitro 
and veriﬁ  ed in various tumor types in vivo. This 
approach provides a sensitive and speciﬁ  c means 
of assessing the transcriptional activity of STAT3, 
independent of the biochemical approaches 
described above. Indeed, a recent study using an 
expression signature for the androgen receptor 
(AR) as an indicator of AR activation was able to 
identify inhibitors of androgen signaling, thereby 
validating this approach (Hieronymus, 2006). 
Furthermore, with the development of targeted 
signal transduction inhibitors for the treatment of 
gliomas and other tumors, the ability to identify 
biomarkers to allow patient selection and monitor-
ing of pharmacodynamics becomes more impor-
tant. Identiﬁ  cation of heightened expression of 
STAT3 target genes in general, and perhaps 
selected STAT3 target genes in particular, may 
allow the identiﬁ  cation of suitable biomarkers.
Given the nature of the data sets used in this 
study, it was not possible to obtain pathologic 
specimens to directly assess the phosphorylation 
status of STAT3. We have shown a high correlation 
between histological evidence of STAT3 activa-
tion (as measured by nuclear staining with an 
antibody to tyrosine-phosphorylated STAT3) and 
a STAT3 gene expression proﬁ  le in breast cancer 
(Alvarez, 2005). As noted, the gene expression 
proﬁ  le may be a more powerful predictor of STAT3 
function, and the use of gene expression for glioma 
classiﬁ  cation has been established as a powerful 
prognostic tool (Nutt, 2003). Nonetheless, it would 
be of interest to determine the correlation between 
histological activation of STAT3 and a STAT3 gene 
expression proﬁ  le in a prospective validation study 
in gliomas. Similarly, very little clinical information 
was available with these data sets. A validation 
study with sufﬁ  cient clinical data to allow a mul-
tivariate analysis of the predictive value of a STAT3 
gene expression proﬁ  le would also be desirable.
The finding of a STAT3 gene expression 
signature in gliomas can have several implications, 
and suggests further areas for study. First, the 
enhanced expression of STAT3 target genes may 
reﬂ  ect the activation of speciﬁ  c tyrosine kinase 
pathways, such as those downstream of the EGF or 
PDGF receptors (Mizoguchi, 2006). Thus, gliomas 
displaying a STAT3 signature might be particularly 
sensitive to the use of an appropriate kinase inhib-
itor. Second, given the particularly poor prognosis 
of tumors with a STAT3 signature, and the possibil-
ity that STAT3 targets may promote invasion and 
104STAT3 target gene expression in gliomas
Translational Oncogenomics 2007: 2 
angiogenesis, a more aggressive therapeutic 
strategy may be warranted in patients with this 
subset of gliomas. Finally, as STAT3 inhibitors are 
developed, tumors expressing a STAT3 gene 
expression signature may be most appropriate for 
initial clinical trials (Frank, 2006).
Advances in the treatment of gliomas will likely 
arise from an enhanced understanding of the 
molecular pathogenesis of these tumors, and devel-
oping the means to target specific signaling 
abnormalities. The ﬁ  nding that STAT3 is activated 
commonly in gliomas, and that a STAT3 gene 
expression signature connotes a worse prognosis, 
reﬂ  ects the likelihood that STAT3 target genes 
underlie key aspects of the biology of these tumors. 
Focusing on STAT3 and its target genes may 
provide critical information for the molecular 
characterization of gliomas and for the develop-
ment of targeted therapeutic interventions.
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